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metastases: technical results, clinical outcome and factors potentially influencing 
survival 
 
ABSTRACT 
Background: the purpose of this study was to retrospectively assess the technical and clinical 
outcomes, overall survival and prognostic factors for prolonged survival after yttrium-90 
radioembolization as a salvage therapy for patients with chemorefractory liver-only or liver-
dominant colorectal metastases. 
Material and Methods: from January 2005 till January 2014, all the patients selected for  
yttrium-90 radioembolization to treat chemorefractory colorectal liver metastases were 
identified. Demographic, laboratory, imaging and dosimetry data were collected. Post-
treatment technical and clinical outcomes were analysed as well as overall survival; finally 
several factors potentially influencing survival were analysed. 
Results: 88 patients were selected for angiographic workup; 71 patients (81%) finally 
underwent catheter-directed yttrium-90 microsphere infusion into the hepatic artery 25 days 
(standard deviation 13 days) after angiographic workup. Median infused activity was 
1809 MBq; 30-day toxicity included: fatigue (n=39; 55%), abdominal discomfort (n=33; 
47%), nausea (n=5; 7%), fever (n=14; 20%), diarrhea (n=6; 9%), liver function abnormalities 
and elevated bilirubin (transient) (n= 3; 4%). Gastric ulcer was found in 5 patients (7%). A 
late complication was radioembolization-induced portal hypertension (REIPH) in 3 patients 
(4%). Median time to progression in the liver was 4.4 months. Estimated survival at 6 and 12 
months was 65% and 30%, respectively, with a 50% estimated survival after 8.0 months in 
this group of chemorefractory patients. Prognostic factors for worse survival were  high 
preprocedural bilirubin, alkaline phosphatase and tumor volume levels. 
Conclusion: yttrium-90 microsphere radioembolization for chemorefractory colorectal liver 
metastases has an acceptable safety profile with a 50% estimated survival after 8.0 months. 
Pretreatment high bilirubin, alkaline phosphatase and tumor volume levels were associated 
with early death. 
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INTRODUCTION 
Colorectal cancer is the second most common cancer in Europe and 15 – 25% of patients 
develop liver metastases. If these patients are ineligible for local ablative therapies like 
radiofrequency ablation (RFA) or for surgical resection, chemotherapeutic treatment remains 
the therapeutic mainstay for this patient population with overall survival beyond 2 years [1-2]. 
For more than a decade, the transarterial administration of radioactive yttrium-90 (90Y) 
microspheres (called selective internal radiation therapy (SIRT) or radioembolization) has 
been under evaluation as a promising additional, locoregional tool in the management of 
patients with liver-only or liver-dominant metastatic colorectal cancer (mCRC). Recently, it 
has been demonstrated that the combination of 5-fluorouracil (5-FU) and 90Y 
radioembolization results in improved survival compared to treatment with 5-FU alone [3] in 
chemorefractory patients with liver-only or liver-dominant mCRC. Based on these findings, 
radioembolization is recommended in the guidelines from the European Society of Medical 
Oncology (ESMO) for patients with liver-limited metastases in whom the available 
chemotherapeutic options have failed [2]. 
 
 
 
 
Several observational cohort studies [4-10] as well as a few meta-analyses dealing with 
radioembolization for chemorefractory mCRC have been published, all of them 
demonstrating the relative safety of the radioembolization technique and the potential for 
better survival. However, only limited data on late toxicity of  90Y in this patient population 
are available [11-13]. Additionally, little information is available about potential prognostic 
factors for prolonged survival. Postprocedural radiological response seems to be the best 
prognostic parameter for better survival. However, no data are available on the potential for 
use of preprocedural (laboratory and radiological) parameters for survival prognosis. 
In this manuscript, we report the early and late side-effects of radioembolization in a ‘real 
world’ patient population with chemorefractory mCRC at a tertiary referral centre for 
digestive cancers over a 9 year time span. Furthermore, we report overall survival and have 
analysed the prognostic potential of preprocedural factors for prediction of improved survival. 
 
MATERIALS AND METHODS 
Patient demographics 
From January 2005 until January 2014, 88 patients with chemorefractory colorectal liver 
metastases were selected for 90Y radioembolization by the institutional tumor board for 
digestive cancers at University Hospitals Leuven, including medical, surgical and radiation 
oncologists, pathologists, interventional and diagnostic radiologists and nuclear medicine 
physicians. 
All patients presented with colorectal liver metastases refractory to several lines of 
chemotherapy, including oxaliplatin and irinotecan-based schemes, with no indication for 
surgical resection or local ablative treatments. Tumor load within the liver as well as 
extrahepatic metastatic spread were assessed by body computed tomography (CT) and/or 18F-
fluorodeoxyglucose positron emission tomography (PET) with or without CT. 
Patients gave informed consent for the 90Y radioembolization workup and treatment after 
being informed about the different steps of the treatment and the effect of radiation on the 
metastases and the residual liver parenchyma. The local Ethics Committee gave approval for 
this retrospective study. 
Inclusion criteria for patient selection were: 
- confirmed histological diagnosis of colorectal cancer 
- unresectable liver metastases 
- ECOG status 0-1 
- Liver-limited or liver-predominant disease 
- no previous external beam radiotherapy to the liver 
- adequate bone marrow reserve, including granulocytes > 1500*109/L and platelets > 
60.000*109/L 
- no contraindication for selective angiography, including normal renal function (serum 
creatinine < 1.8 mg/ml) and no allergy to iodinated contrast medium 
- bilirubin level < 2.5 mg/ml 
- lung shunt fraction (LSF) < 20% assessed during post-angiographic workup 
99mtechnetium-macroaggregated albumin (99mTc-MAA) scintigraphy 
 
Radiological technique 
The interventional radiological technique for 90Y delivery into the liver tumors consists of an 
angiographic workup including 90mTc-MAA planar scintigraphy and SPECT (/CT) and 
transcatheter infusion of the 90Y-loaded microspheres  into the hepatic artery a few weeks 
later, performed in accordance with previously published guidelines and technical 
angiographic reviews [14,15]. 
Briefly, under local anesthesia, access is gained to the right common femoral artery with use 
of a 4 French (F) introducer sheath (Boston Scientific, Natick, MA, USA). Selective 
angiography of the celiac trunk and superior mesenteric artery is performed using a 4 F 
Simmons 1 catheter (Impress®, Merit Medical, South Jordan, UT, USA). Enterohepatic 
arteries are identified and, if indicated, coil embolized (Target microcoils, Boston Scientific, 
Natick, MA, USA or Microtornado, Cook Medical, Bloomington, IN, USA) through a 
microcatheter (Progreat 2.7, Terumo Europe, Leuven, Belgium or Maestro 2.4, Merit 
Medical, South Jordan, UT, USA). Finally, the microcatheter is positioned in the proximal 
lobar hepatic artery/arteries, which is the same position as for the 90Y microsphere infusion, 
and a diagnostic volume of 99mTc-MAA is injected. Typically, 100 mega-Becquerel (MBq) is 
injected in the right lobe and 50 MBq in the left lobe of the liver.  
After sheath removal and femoral compression for 10 minutes, the patient is immediately 
referred to the nuclear medicine department for planar scintigraphy within one hour after 
99mTc-MAA injection to determine the LSF and SPECT (/CT) evaluation for the assessment 
of extrahepatic and intratumoral 99mTc-MAA deposition [16]. 
The selective internal radiation therapy (SIRT) procedure was then performed between 2 and 
5 weeks after the angiographic workup with the use of resin 90Y microspheres (SIR spheres, 
Sirtex Inc, Cosgrove, Australia). The SIRT procedure, also performed under local anesthesia, 
included correct positioning of the tip of the microcatheter within the hepatic artery/arteries at 
the same position as the injection of 99mTc-MAA during workup. In no patient, (super-) 
selective infusion of 90Y microspheres into a tumor feeding artery was performed. No 
chemotherapeutic drugs were administered immediately before or after the SIRT procedure; 
anti-emetics and morphine derivatives were given when required. Steroids, proton pump 
inhibitors or antibiotics were not systematically administered.  
All bilobar SIRT procedures were performed in one session. 
 90Y microsphere activity calculation 
Activity calculation was mainly performed using the body surface area (BSA) method.  In 
patients with diffuse bilobar disease the activity injected was the one calculated using the 
BSA method. Initially these values were reduced if the LSF was >10% (10-15%: reduction to 
80%; >15%-20%: 60%) but in patients treated later the activity was only reduced if the 
calculated dose would result in a lung dose of more than 30 Gy, with a reduction leading to a 
30 Gy lung dose. In patients with unilobar disease in which activity escalation could be 
performed the partition model  was used. 
 
90Y brehmsstrahlung imaging 
Patients were imaged on the day of the 90Y microsphere infusion or the next day.  
Brehmsstrahlung imaging was performed on the same gamma cameras as used for the 99mTc-
MAA scintigraphy. No 90Y PET imaging was performed as we did not have a time-of-flight 
PET camera during the time period studied. 
 
Follow-up 
All patients were clinically followed up by the attending medical oncologist and by their 
general practitioner. Early complications were defined as treatment-related complications 
occurring within 30 days after infusion of 90Y microspheres. Late complications are defined 
as 90Y-related side effects occurring later than 30 days after infusion of 90Y microspheres.  
Radiological follow-up was performed with CT or 18F-FDG-PET-CT with a time interval of 
2 months until progression of disease; additional CT-scan was performed if a new clinical 
event occurred. Once the patient presented with progression of disease, it was decided, after 
discussion with the patient and his/her family, if further treatment and/or radiological follow-
up was performed.  
Grading of side effects was based on National Cancer Institute – Common Terminology 
Criteria for Adverse Events (NCI-CTCAE) version 4.0.  
 
Study design 
Aims of the study were assessment of time to tumor progression in the liver, overall survival 
after 90Y microsphere radioembolization, tolerability of the treatment and late complications 
related to 90Y infusion. Additionally, several factors potentially influencing survival were 
analysed. The factors are discrete variables including synchronous versus metachronous liver 
metastases and total activity versus reduced activity delivery; continuous variables analysed 
were: laboratory data including platelet count, carcinoembryonic antigen, bilirubin, creatinine, 
aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase and LSF, 
total administered activity in MBq and total tumor volume. 
 
Statistical analysis 
Kaplan-Meier estimates were used for overall survival curves; frequencies and percentages 
are presented for categorical variables. Mean and standard deviation (STD) as well as median 
and quartiles are given for continuous variables. Univariable analysis of the prognostic value 
of variables for overall survival after 90Y radioembolization was carried out using Cox 
proportional hazards regression. Effects of continuous variables were explored by comparing 
linear and non-linear associations, including quadratic and cubic splines based trends. 
A multivariable prediction model for overall survival after 90Y radioembolization was based 
on the multiple imputation procedure for model building, given the considerable number of 
missing values for some predictor variables. Missing values were imputed 10 times, creating 
10 complete data sets. Imputation was based on linear or logistic regression for continuous 
and binary variables, respectively, and on predictor variables. Given the fact that all selected 
variables in the final model were completely observed (no missing values), interference is 
based on the observed data only. 
The Concordant Probability Estimate (CPE) or C-index is determined as an indicator of the 
discriminatory power of the risk prediction model for overall survival after 
90Y radioembolization. This index takes values between 0.5 (discriminator no better than 
random) and 1 (perfect discrimination). Interpretation is similar to the (area under the curve) 
(AUC) or C-index for binary responses, indicating the probability that the predictions for a 
random pair of subjects are concordant with their outcomes [17]. 
All tests are two-sided and a 5% significance level is assumed for all tests. All analyses have 
been performed using SAS software, version 9.3 of the SAS System for Windows (SAS 
Institute Inc., Cary, NC, USA). 
 
RESULTS 
Initially, 88 patients were selected for angiographic workup; however 17 out of these 88 
patients (19%) were excluded from further SIRT therapy based on an LSF of > 20% (n=7); 
leakage of 99mTc-MAA to the gastroduodenal area, not correctable by repeat angiography and 
coil embolization (n=1), prior external beam radiotherapy to the liver unknown at the time of 
angiographic workup and progression of disease resulting in excessive extrahepatic disease 
during the time period between angiographic workup and the SIRT procedure (n=8). Overall, 
71 patients underwent both angiographic workup and transcatheter SIRT therapy and these 
patients are studied below. 
 
 
Demographic data 
The patients’ demographics are summarized in Table I. The majority of included patients 
were men, presenting with  synchronous, bilobar colorectal liver metastases with no 
extrahepatic tumor load. 
Laboratory data, including platelet count, carcinoembryonic antigen (CEA), bilirubin, kidney 
and liver function tests are summarized in Table II. 
All patients (n=71 ; 100%) had progressed on second line chemotherapy ; 44 out of 71 
patients (62%) had progressed on third line chemotherapy. In total 40 out of 71 patients 
(56%) received cetuximab prior to 90Y radioembolization. 
At the time inclusion for SIRT-therapy, 2 out of 71 included patients (3%) had a 
bilirubine level > 2.5 mg/ml and 20 out of 71 patients (28%) had a bilirubine level  > 1 
mg/dl. 
 
Radiological and nuclear medicine data 
During angiographic workup, the gastroduodenal artery was coiled in 60 patients (85%), the 
right gastric artery in 30 patients (42%), the left gastric artery in 3 patients (4%), a pancreatic 
artery in 2 patients (3%), the supraduodenal artery in 1 patient (1%) and the phrenic artery in 
1 patient (1%). Finally, flow redistribution was obtained after coil embolization of the left 
hepatic artery in 4 patients (6%) and of the accessory branch to segment 4 in 2 patients (3%). 
The LSF based on the 99mTc-MAA scintigraphy had a mean value of 8% with a standard 
deviation of 3.5%, a median value of 7.8% with an IQR between 5.9% and 9.8% and a range 
between 3% and 19% (Fig. 1). The mean time interval between the workup angiographic 
procedure and the 90Y infusion therapy was 25 days (standard deviation: 13 days). 
The total liver volume, liver tumor volume, diameter of the largest liver metastasis, the 
number of patients treated with a reduced activity and the total activity of 90Y microspheres 
administered to the patients are summarized in Table III. 
  
Technical and clinical outcome 
1.  Early and late 90Y microsphere related toxicity 
90Y microsphere related toxicity detected during the first month after treatment included: 
NCI-CTCAE grade 1 side effects, including fatigue (n=39 ; 55%) and fever (n=14 ; 20%); 
NCI-CTCAE grade 2 side effects, including abdominal discomfort (n=33 ; 47%), nausea (n=5 
; 7%) and diarrhea (n=6 ; 9%) and NCI-CTCAE grade 3 side effect, including procedure-
related liver insufficiency, defined as twofold increase in bilirubin level within 30 days after 
90Y infusion (n=3 ; 4%). 
Late complications, defined as 90Y -related side effects detected later than 30 days after the 
90Y infusion were NCI-CTCAE grade 2 side effects, including gastric ulcers, potentially 
related to non-target infusion of 90Y -loaded microspheres into the gastroduodenal 
vasculature, which were endoscopically confirmed in 5 patients (7%). One patient required a 
partial gastrectomy for definitive management of these ulcers. Finally, NCI-CTCAE grade 3 
late complications were identified in another 3 patients (4%). These late adverse events were 
fibrotic/cirrhotic changes in the liver parenchyma, associated with symptoms of portal 
hypertension (radioembolization-induced portal hypertension, REIPH): one patient presented 
with variceal upper gastrointestinal bleeding, while 2 other patients presented with benign, 
refractory ascites respectively 19, 19 and 12 months after initial 90Y radioembolization (Fig. 
2a-b, Fig. 3a-b). The upper gastrointestinal, variceal bleeding was managed using endoscopic 
techniques; the refractory ascites by repeated parascenteses. 
 
2.  Disease free survival, time to tumor progression in the liver and overall survival. 
Radiological follow-up data for the assessment of disease free survival and time to tumor 
progression in the liver was available in 61 out of 71 patients (86%), demonstrating a median 
disease free survival of 3 months (mean 4.6 months, standard deviation 4.1 months)  and a 
median time to progression in the liver of 4 months (mean 6.0 months, standard deviation 5.1 
months). One patient (1.5%) could be downstaged for combined surgical segmentectomy in 
the right liver lobe and radiofrequency ablation in the left liver lobe. Overall, estimated 
survival at 6 and 12 months is 65% and 30% respectively with a 50% estimated mortality 
after 8.0 months (Table IV and Fig. 4). 
 
3.  Factors potentially influencing survival 
Univariate analysis, summarized in Table V, demonstrates an increased risk of early mortality 
for increased baseline alkaline phosphatase values; a non-linear correlation was found 
between bilirubin levels and total tumor volume and prolonged survival: patients with the 
lowest baseline values for bilirubin and total tumor volume had a lower risk of early 
mortality, whereas intermediate values had the highest risk of early death (Fig. 5, Fig. 6). 
Increased AST levels are associated with a higher risk of early mortality, but the correlation is 
non-linear with a flattening of the effect for the lowest and highest levels (Fig. 7). 
Finally, multivariate analysis demonstrates a linear increase in early mortality after SIRT in 
patients with higher baseline alkaline phosphatase levels: for each increase by 10 units, the 
risk of death rises by 1% (Fig. 8). The CPE value of this model is 0.65, meaning that in 65% 
of patient pairs the model will give a correct prognosis for which of the two patients the best 
survival can be predicted (Table VI). 
 
 
DISCUSSION 
This report confirms the low complication rate related to the infusion of 90Y microspheres into 
the liver, in line with other studies dealing with SIRT for treatment of colorectal liver 
metastases: prolonged abdominal pain, fatigue and radiation-induced gastroduodenal ulcers 
were identified in respectively 46%, 55% and 7%, which is within the range of other 
published experiences [12]. We also identified 3 patients (4%) presenting with a significant 
increase in bilirubin levels within 30 days after the 90Y infusion. This phenomenon may be 
related to radioembolization-induced liver disease, although rapid progression of liver disease 
may potentially also result in elevated bilirubin levels. Three patients (4%) presented with 
cirrhosis-like changes in the liver parenchyma, associated with severe symptoms of portal 
hypertension, including refractory ascites (n=2) and variceal upper gastrointestinal bleeding 
(n=1), respectively 19, 12 and 12 months after 90Y treatment. This complication, which we 
defined as radioembolization-induced portal hypertension, is most probably an extreme 
clinical presentation of the radiation-induced liver fibrosis described by Jacobs et al. [11]. 
Potentially, this late complication might be avoided if these patients had received 
corticosteroids as suggested by Sangro et al [18]. As these symptoms of radioembolization-
induced portal hypertension were identified at one year or later after SIRT-therapy, the 
potential incidence of this side effect might be much higher than 4% if patients with a 
potential better survival prognosis will be treated with SIRT, like patients treated with 
SIRT in an earlier stage of their disease. 
The general overall survival after 90Y radioembolization in our cohort of chemorefractory 
colorectal cancer patients shows a median overall survival of 8.0 months and 30% of the 
treated patients were still alive after 1 year of follow-up.  In a systematic review, Saxena et al. 
[19] found an overall survival for patients with colorectal liver metastases who were treated 
with 90Y microspheres ranging from 8.0 months to 36 months. The lowest survival results 
were found in the patient populations previously treated with the most lines of intravenous 
chemotherapy, as in our patient population [20]. Additionally, we did not administer an 
intravenous 5-FU infusion  immediately after the 90Y infusion as described by Hendlisz et al. 
[3], which might also have a beneficial effect on the survival outcome. The median overall 
survival of 8.0 months after 90Y -radioembolization for colorectal liver metastases in patients 
refractory to all types of chemotherapy seems to be somewhat better than the overall survival 
after best supportive care (5.0 months) or after regorafenib (6.4 months) (26). However, a 
prospective, randomized trial comparing 90Y to Regorafenib might give the answer to better 
determine the place of these treatments in patients with colorectal metastases, refractory to all 
types of currently available chemotherapies. 
The median time to tumor progression in the liver was 4.4 months, which is in line with other 
studies dealing with the same patient population [2]. In this cohort of patients with 
chemorefractory colorectal liver metastases, downstaging to surgical resection remains rare: 
only 1 patient was finally able to be resected and these data confirm those obtained by 
Cosimelli et al. [5]. 
We also found a substantial number of patients (n=19) who were excluded from 90Y 
microsphere infusion after the workup procedure. Exclusion from 90Y microsphere infusion 
was mainly related to a high liver-lung shunt of > 20% ( n=7) or to rapid disease progression 
during the interval between angiographic workup and 90Y radioembolization (n=8). The mean 
time interval seems to be relatively long (25 days) and the number of excluded patients could 
possibly be reduced if a shorter time interval could be considered. 
We also analysed several pre-interventional biochemical and imaging parameters which 
potentially influence the overall survival. In a univariable analysis, higher alkaline 
phosphatase, AST and ALT values were associated with a higher risk of early mortality; for 
bilirubin and total tumor volume values, better survival seems to be observed for the lowest 
values while intermediate values were associated with an increased risk of early mortality. A 
flattening or even a discrete decrease in early deaths was noted for the highest pre-treatment 
levels of bilirubin and total tumor load. Based on these results, patients with both borderline 
high bilirubin and borderline high tumor volume levels should not be excluded from 90Y  
radioembolization, which is in line with the results of Jacobs et al. [6]. However, other studies 
suggest a higher risk of early mortality in patients with a higher tumor burden [21-24]. 
The presented study cannot confirm the results of Deipolyi et al. [25] showing an increased 
risk of early widespread metastatic growth and subsequently early mortality in those patients 
with a high liver-lung shunt (p=0.1087). Deipolyi et al [25] hypothesize that a higher liver-
lung shunt is associated with larger vascular, intratumoral shunts between the hepatic artery 
and hepatic vein, thereby facilitating malignant cell migration from the liver to the lungs and 
other organs. 
In a multivariate analysis, a higher alkaline phosphatase level and an intermediate bilirubin 
level are associated with a higher risk of early mortality. 
In conclusion, this study confirms the good safety profile of 90Y microspheres administered in 
the hepatic artery for the treatment of colorectal liver metastases with an overall survival of 
8 months in chemorefractory mCRC patients with liver-limited or liver-predominant 
metastases. However, a relatively high number of patients were excluded from further 
treatment after the workup mainly due to a high liver-lung shunt or rapid disease progression 
during the time period between the workup and 90Y microsphere administration. 
Pre-interventional higher bilirubin, alkaline phosphatase and AST levels as well as a higher 
pretreatment tumor burden are associated with higher risk of early mortality. 
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Table I: Demographic data of included patients 
 
Variable    Statistic  Total = 71   
Sex  
   M     n/N (%)  51/71 (72%) 
   F     n/N (%)  20/71 (28%) 
Age     N   71 
     Mean   62.5 
     STD     9.5 
     Median  62.0 
     IQR   (56 – 70) 
     Range   (42 – 82) 
Synchronous/metachronous 
  Metachronous   n/N (%)  23 (32%) 
   Synchronous   n/N (%)  48 (68%) 
Uni/bilobar involvement 
  Unilobar    n/N (%)  13 (18%) 
  Bilobar    n/N (%)  58 (82%) 
Extrahepatic disease 
  No     n/N (%)  49 (69%) 
  Yes     n/N (%)  22 (31%) 
Previous liver surgery  n/N (%)  10 (14%) 
Previous RF ablation   n/N (%)    6   (8%) 
Previous FOLFOX   n/N (%)  69 (97%) 
Previous FOLFIRI   n/N (%)  67 (94%) 
Previous biologicals 
 Bevacizumab   n/N (%)  29 (41%) 
 Cetuximab   n/N (%)  40 (56%) 
 
 
 
IQR: interquartile range 
STD: standard deviation 
 
 
Table II: Laboratory data before SIRT 
 
Variable     statistic   All   
Platelet count n*109/L   N    71 
      Mean    253 
      STD    116 
      Median   237 
      IQR    (168 – 316) 
      Range     (88 – 694) 
 
CEA, µg/L     N    71 
      Mean    853 
      STD     2918 
      Median   119 
      IQR    (36.5 – 692) 
      Range    (1.7 – 23890) 
 
Bilirubin mg/dL    N    71 
      Mean    0.9 
      STD    0.57 
      Median   0.8 
      IQR    (0.5 – 1.1) 
      Range    (01 – 2.7) 
 
Creatinine mg/dL    N    71 
      Mean     0.8 
      STD    0.25 
      Median   0.8 
      IQR    (0.7 – 1.0) 
      Range     (0.4 – 1.8) 
 
AST U/L     N    71 
      Mean    53 
      STD    44 
      Median   40 
      IQR    (32 – 55) 
      Range    (19 – 258) 
 
ALT U/L     N    71 
      Mean    42 
      STD    34 
      Median   31 
      IQR    (21 – 50) 
      Range    (4 – 204) 
 
Alk.phosph. U/L    N    71 
      Mean    548 
      STD    401 
      Median   410 
      IQR    (266 – 714) 
 
IQR: interquartile range 
STD: standard deviation 
AST: aspartate transaminase 
ALT: alanine transaminase 
Alk.phosph.: alkaline phosphatase 
 Table III: liver volume, tumor volume and total administered activity 
 
 
 
 
Variable      statistic   all   
 
Total liver tumor volume/total liver volume N    49 
      Mean    34.9 
      STD    28.1 
      Median   26.7 
      IQR    14.5 - 50 
      Range    0.7 - 120 
 
Diameter of the largest liver metastasis (mm) N    71 
      Mean    68.2 
      STD    28.12 
      Median   69.0 
      IQR    (45.0; 85.0) 
      Range    (23.0; 146.0) 
 
Full versus reduced administered activity 
Activity reduction    n/N (%)     6/48 (12.5%) 
Full activity     n/N (%)   42/48 (87.5%) 
 
Total administered activity (MBq)  N    66 
      Mean    1819 
      STD    309 
      Median   1810 
      IQR    (1647 – 1994) 
      Range    (818 – 2454) 
 
 
STD: standard deviation 
IQR: interquartile range 
 Table IV: estimated survival rates of the studied patients 
 
 
Survival in months since SIRT therapy       
      95% confidence interval (CI) 
 
Months       % survival       lower limit       upper limit  
6   65   55   73 
12   30   24   36 
18   20   16   25 
24     6     4     7 
 
Mortality in months since SIRT therapy       
 
      95% confidence interval (CI) 
            months 
Percentile            since 90Y      lower limit                   upper limit 
25%     4     2     6 
50%     8     7     9 
75%   13   10   19 
 
Table V 
 
Univariate analysis for factors of early death 
 
Variable     HR  Lower limit upper limit P-value N obs N events 
Discrete variables 
Syn/meta    1.143 0.670  1.951  0.6231  70 63 
Total/reduced    1.171 0.455  3.013  0.7429  47 42 
 
Continuous variables 
Bili (non-linear)      0.0190  70 63 
Creat     1.098 0.348  3.466  0.8736  70 63 
AST (non-linear)      0.0458  70 63 
ALT     1.089 0.999  1.187  0.0524  70 63 
Platelets    1.005 0.982  1.029  0.6520  70 63 
CEA     1.000 1.000  1.001  0.3793  70 63 
Alc phos    1.011 1.005  1.017  0.0003  70 63 
Tc-scan: %shunt1.060 0.987  1.137  0.1087  70 63 
Total dose    1.000 0.999  1.001  0.5363  65 58 
Tumor volume      0.0034  48 43 
 
 
Multivariate analysis for factors of early death 
 
Variable  HR         Lower limit Upper limit P-value CPE 
Alk phos  1.010  1.004  1.016  0.0008  0.646 
Bili         0.0021 
 
 
 
HR: Hazard ratio 
Syn/meta: synchronous / metachronous disease 
Total/reduced: total/reduced dose of Y90-microspheres 
Bili: bilirubin 
Creat: creatinine 
AST: aspartate transaminase 
ALT: alanine transaminase 
Platelets: platelet count 
CEA: carcino-embryogen antigen 
Alk phos: alkaline phosphatase 
Tc-scan: Technecium scan 
 
Lower & Upper limit: 95% confidence interval 
 
N obs: number of observations 
N events: number of events 
 
Discrete variables: HR>1 means higher risk for the indicated category, compared to reference. 
HR<1 means lower risk for the indicated category (compared to reference) 
 
Continuous variables (linear association if not mentioned otherwise): 
Units: HR is calculated for a 1-unit or 10-units increase of the level of variable 
HR>1 means higher risk for higher levels; HR<1 means lower risk for higher levels 
Continuous variables with non-linear effects: no HR can be estimated 
 
FIGURE LEGENDS 
 
Fig. 1: schematic overview of the lung shunt fraction (LSF) distribution after intrahepatic 
injection of 99mTc-macroaggregates (99mTc-MAA): mean of 8.3%, standard deviation of 3.5%, 
median of 7.8%, IQR (5.9% - 9.8%) and range (3.0% - 19.1%) 
Fig. 2a-b: 61-year-old man with chemorefractory liver-only disease. a: contrast-enhanced MR 
imaging before 90Y radioembolization shows several, small hypervascular colorectal 
metastases in a non-cirrhotic liver ; b: contrast-enhanced CT scan 12 months after 90Y 
radioembolization reveals progression of disease in the left liver lobe (arrows). Note also the 
irregular liver contour (arrowheads) surrounded by large amount of ascites as seen in cirrhotic 
patients. 
Fig. 3a-b: hematoxylin-eosin staining of a liver biopsy of the patient from Fig. 2: a) 25 x 
magnification and b) 200 x magnification demonstrates  Y 90 microspheres (arrows) within 
portal tracts. Sinusoidal dilatation suggests severe portal hypertension. 
Fig. 4: Kaplan-Meier survival curve shows an estimated survival of 65.2% (55.3% – 73.5%), 
29.5% (23.6 – 35.6) and 20.2% (16.0 – 24.7) after respectively  6, 12 and 18 months. The 
dashed lines represent the 95% confidence interval. 
Fig. 5a: preprocedural bilirubin level (X axis) related to the survival (Y axis) demonstrates a 
non-linear worse survival outcome in patients with low and high preprocedural bilirubin 
levels. 
Fig. 5b: ratio of tumor volume/liver volume (X axis) related to survival (Y axis) demonstrates 
a non-linear better survival outcome in patients with a low and high preprocedural tumor 
volume/liver volume ratio. 
Fig. 5c: preprocedural level of AST (X axis) related to survival (Y axis) demonstrates a non-
linear worse survival outcome in patients with higher preprocedural AST levels. 
Fig. 5d: preprocedural level of alkaline phosphatase (X axis) related to survival (Y axis) 
demonstrates a higher early mortality in patients with a higher preprocedural alkaline 
phosphatase level. 
